VITROS® XT 7600 Integrated System from Ortho Clinical Diagnostics Receives CE Mark

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Ortho Clinical Diagnostics today announced that it has received CE mark for Ortho’s VITROS® XT 7600 Integrated System. By combining Ortho’s proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously, Ortho is introducing digital chemistry to clinical lab management. Digital chemistry brings powerful data intelligence, operational improvements and heightened quality to the lab to help clinical laboratories keep pace with a rapidly evolving global health care environment, without requiring additional lab space.

“Ortho’s VITROS® XT 7600 harnesses the power of our proprietary dry slide technology to deliver even more enhanced, high-quality test results, higher throughput and an improved patient experience, all within the lab’s existing physical footprint,” said Robert Yates, chief operating officer of Ortho Clinical Diagnostics. “It’s a fundamental change to the way labs operate.”

The digital chemistry behind Ortho’s VITROS® XT 7600 is based on three enabling technologies:

  • Dry slide technology.  Unlike traditional wet chemistry systems, which require highly purified water and complex plumbing systems to operate, Ortho’s proprietary dry slide technology does not require water to run.  This eliminates the risk that poor water quality could impact test results.
  • MicroSlide.   A full testing environment on a postage-stamp-sized piece of film enables precise and accurate testing in a waterless environment.
  • Digital imaging technology.  Advanced optics glean significantly more information from testing than has been possible to date, enabling better precision and powerful data intelligence functions in the lab.

In addition, Ortho’s VITROS® XT 7600 increases productivity, with less patient blood sample required, by introducing multi-test processing – the potential to offer two tests per slide instead of one — to clinical chemistry. With XT MicroSlides1, the instrument will provide the ability to pair tests that are frequently ordered for the same patient so they can be run simultaneously. This saves time and space in the lab, and reduces the amount of blood needed for testing, an important advantage for vulnerable patients or those with venous access issues.

“We are an internationally renowned laboratory where quality comes first. The Ortho technology is stable and filters out most common interferences to deliver a high first-pass yield and minimal reruns,” said Phil Craddock-Jones, lab manager, Sheffield Children’s Hospital in the UK. “Ortho’s VITROS® Systems don’t require water to run, which reduces the risk of water contamination.”

The Ortho VITROS® XT 7600 Integrated System has received CE Mark signifying conformance to applicable European Union regulatory requirements and is now available for purchase in numerous countries in Europe, the Middle East, Africa, Asia and Latin America.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.